Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Merck
Moodys
Medtronic
McKinsey
Mallinckrodt
Baxter

Last Updated: August 11, 2022

Investigational Drug Information for Mavrilimumab


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the drug development status for Mavrilimumab?

Mavrilimumab is an investigational drug.

There have been 8 clinical trials for Mavrilimumab. The most recent clinical trial was a Phase 2 trial, which was initiated on July 27th 2020.

The most common disease conditions in clinical trials are Pneumonia, Respiratory Insufficiency, and Inflammation. The leading clinical trial sponsors are Kiniksa Pharmaceuticals, Ltd., Virginia Commonwealth University, and Ospedale San Raffaele.

There are five US patents protecting this investigational drug and ninety-one international patents.

Recent Clinical Trials for Mavrilimumab
TitleSponsorPhase
Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammationKiniksa Pharmaceuticals, Ltd.Phase 2
Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammationVirginia Commonwealth UniversityPhase 2
Study of Mavrilimumab (KPL-301) in Participants Hospitalized With Severe Corona Virus Disease 2019 (COVID-19) Pneumonia and Hyper-inflammationKiniksa Pharmaceuticals, Ltd.Phase 2/Phase 3

See all Mavrilimumab clinical trials

Clinical Trial Summary for Mavrilimumab

Top disease conditions for Mavrilimumab
Top clinical trial sponsors for Mavrilimumab

See all Mavrilimumab clinical trials

US Patents for Mavrilimumab

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Mavrilimumab See Plans and Pricing Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein CureVac AG (Tubingen, DE) See Plans and Pricing
Mavrilimumab See Plans and Pricing Bispecific chimeric antigen receptors and methods of use thereof to treat cancer Seattle Children's Hospital (Seattle, WA) See Plans and Pricing
Mavrilimumab See Plans and Pricing Binding-triggered transcriptional switches and methods of use thereof The Regents of the University of California (Oakland, CA) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Moodys
Medtronic
McKinsey
Mallinckrodt
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.